Observer variation in immunohistochemical analysis of protein expression, time for a change? (Q53004389)

10 May 2018

title

Observer variation in immunohistochemical analysis of protein expression, time for a change? (English)

1 reference

10 May 2018

1 reference

2

1 reference

10 May 2018

author name string

Kirkegaard T

1

1 reference

10 May 2018

Tovey S

3

1 reference

10 May 2018

McGlynn LM

4

1 reference

10 May 2018

Krishna SN

5

1 reference

10 May 2018

Mukherjee R

6

1 reference

10 May 2018

Tam L

7

1 reference

10 May 2018

Munro AF

8

1 reference

10 May 2018

Dunne B

9

1 reference

10 May 2018

Bartlett JM

10

1 reference

10 May 2018

publication date

1 June 2006

1 reference

10 May 2018

published in

Histopathology

1 reference

10 May 2018

volume

48

1 reference

10 May 2018

issue

7

1 reference

10 May 2018

page(s)

787-794

1 reference

10 May 2018

HER-2 and TOP2A coamplification in urinary bladder cancer.

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2006.02412.X

Tissue microarrays for miniaturized high-throughput molecular profiling of tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2006.02412.X

Immunohistochemical detection of steroid receptors in breast cancer: a working protocol. UK Receptor Group, UK NEQAS, The Scottish Breast Cancer Pathology Group, and The Receptor and Biomarker Study Group of the EORTC

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2006.02412.X

The clinical evaluation of HER-2 status: which test to use?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2006.02412.X

Evaluating HER2 amplification and overexpression in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2006.02412.X

Statistical evaluation of agreement between two methods for measuring a quantitative variable.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2006.02412.X

Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2006.02412.X

Type I receptor tyrosine kinases are associated with hormone escape in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2006.02412.X

Can molecular markers predict when to implement treatment with aromatase inhibitors in invasive breast cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2006.02412.X

Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2006.02412.X

Cyclooxygenase 2 (COX2) expression is associated with poor outcome in ER-negative, but not ER-positive, breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2006.02412.X

A role for BRCA1 in sporadic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2006.02412.X

The role of c-Jun and c-Fos expression in androgen-independent prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2006.02412.X

Her2/neu expression predicts the response to antiaromatase neoadjuvant therapy in primary breast cancer: subgroup analysis from celecoxib antiaromatase neoadjuvant trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2006.02412.X

Low HER2/neu gene expression is associated with pathological response to concurrent paclitaxel and radiation therapy in locally advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2006.02412.X

The Role of Biological Markers as Predictors of Response to Preoperative Chemotherapy in Large Primary Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2006.02412.X

What the clinician needs from the pathologist: evidence-based reporting in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2006.02412.X

Comparison of different antibodies for detection of progesterone receptor in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2006.02412.X

Reliability of immunohistochemical demonstration of oestrogen receptors in routine practice: interlaboratory variance in the sensitivity of detection and evaluation of scoring systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2006.02412.X

Chromosome 17 aneusomy is associated with poor prognostic factors in invasive breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2006.02412.X

10.1111/J.1365-2559.2006.02412.X

21 January 2018

Identifiers

DOI

1 reference

10 May 2018

PubMed ID

16722926

1 reference

10 May 2018